The brief negative symptom scale (BNSS): Sensitivity to treatment effects

The Brief Negative Symptom Scale (BNSS) grew out of a recommendation by the NIMH-sponsored Consensus Development Conference on Negative Symptoms that a scale based on contemporary concepts be developed. We assessed sensitivity to change of the BNSS in a trial of MIN-101, which showed efficacy for negative symptoms (PANSS pentagonal model) at daily doses of 32 and 64mg/day. Using mixed-effects model for repeated measures, we examined change in BNSS total score and in the BNSS factors of anhedonia/avolition/asociality (AAA), and expressivity (EXP).

Source: Schizophrenia Research - December 21, 2017 Category: Psychiatry Authors: Brian Kirkpatrick, Jay B. Saoud, Gregory P. Strauss, Anthony O. Ahmed, Kazunori Tatsumi, Mark Opler, Remy Luthringer, Michael Davidson Source Type: research